Keytruda hits endpoints in triple-negative breast cancer

13th February 2020 Uncategorised 0

Earlier this week, NICE released a draft guidance rejecting Keytruda when used in combo with Pfizer’s Inlyta (axitinib) to treat advanced renal cell carcinoma.

More: Keytruda hits endpoints in triple-negative breast cancer
Source: News